MentionFox
Home › Executive changes › CorMedix Inc.
Leadership changes · CRMD · SEC Form 8-K, Item 5.02

Leadership changes at CorMedix Inc. (2026)

Before you join, sell to or invest in CorMedix Inc.

MentionFox check on CorMedix Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/cormedix

Check CorMedix Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about CorMedix Inc.?

Who joined and who left CorMedix Inc. (CRMD)? 1 filing reported on 2026-01-08, each cited to the company's own filing.

As of November 14, 2026, CorMedix Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 8, 2026 (Form 8-K, January 8, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Deep Track Capital, LP also filed stake reports on 60 other companies ↓

Sell to companies like CorMedix Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-01-08

CorMedix Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-08. Every row below is cited to the filing it comes from, and this page adds each new change as CorMedix Inc. files it.

Also on the record for CorMedix Inc.

DateRecordFigureOur pageSource
June 12, 2026Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER5.9% of the class5%+ stakesSource
June 12, 2026Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER5.9% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP7.94% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
January 2, 2026Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER5.8% of the class5%+ stakesSource
December 1, 2025Stake report, Schedule 13G, by Deep Track Capital, LP6.29% of the class5%+ stakesSource
August 8, 2025Stake report, Schedule 13G/A, by SHAIBATALHAMD AYMEN ABDALKADER6.2% of the class5%+ stakesSource

Selling to them or working with them? See who runs CorMedix Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on CorMedix Inc. and the records around it.

CorMedix Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on CorMedix Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on CorMedix Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on CorMedix Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    8 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-08Reportednot named in the filing8-K, 2026-01-08
Selling to CorMedix Inc.?

New leaders reset buying decisions — get the Full Report on CorMedix Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch CorMedix Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at CorMedix Inc., with the record behind each one.

Find candidates like senior executive at CorMedix Inc.

Every change, in the filing's words

Filed 2026-01-08 · 8-K

Reported

Mr. Todisco's appointment as Chairman of the Board, effective January 8, 2026, was approved by the Board on January 5, 2026.

Also stated in this filing

  • On January 5, 2026, the Company entered into an amended and restated executive employment agreement (the "A&R Employment Agreement") with Joseph Todisco, the Company's Chief Executive Officer.
  • Pursuant to the A&R Employment Agreement, Mr. Todisco will continue to serve as the Company's Chief Executive Officer and will also serve as the Chairman of the Company's board of directors (the "Board").
  • Pursuant to the A&R Employment Agreement, Mr. Todisco's annual base salary increased from $665,000 to $750,000 effective as of January 1, 2026 and his target annual bonus opportunity increased from 65% to 75% of his base salary, beginning with the Company's 2026 fiscal year, with the actual amount of any annual bonus to be determined based on achievement of Company and individual objectives set by the Board (or its compensation committee) after consultation with Mr. Todisco.
  • Mr. Todisco will also be eligible to receive grants pursuant to the Company's 2019 Omnibus Stock Incentive Plan or any successor thereto (the "Equity Plan") from time to time as determined by the Board (or its compensation committee).
  • The A&R Employment Agreement also contains customary confidentiality and non-disparagement covenants and non-competition and non-solicitation of employees and customers covenants that apply during employment and for a period of 18 months following any termination of employment.

Tools for this story

Each opens in a new tab, filled in for CorMedix Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cormedix
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of CorMedix Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/cormedix